146 related articles for article (PubMed ID: 32622782)
41. Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?
Specht L
Curr Treat Options Oncol; 2016 Jan; 17(1):4. PubMed ID: 26739151
[TBL] [Abstract][Full Text] [Related]
42. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J
J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.
Hutchings M; Mikhaeel NG; Fields PA; Nunan T; Timothy AR
Ann Oncol; 2005 Jul; 16(7):1160-8. PubMed ID: 15939713
[TBL] [Abstract][Full Text] [Related]
44. Nodal FDG-PET/CT uptake influences outcome and relapse location among esophageal cancer patients submitted to chemotherapy or radiochemotherapy.
Jimenez-Jimenez E; Mateos P; Ortiz I; Aymar N; Roncero R; Gimenez M; Pardo J; Sabater S
Clin Transl Oncol; 2019 Sep; 21(9):1159-1167. PubMed ID: 30661172
[TBL] [Abstract][Full Text] [Related]
45. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen.
Picardi M; Soricelli A; Grimaldi F; Nicolai E; Gallamini A; Pane F
Ann Oncol; 2011 Mar; 22(3):671-680. PubMed ID: 20693297
[TBL] [Abstract][Full Text] [Related]
46. Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy.
Bartlett NL
Am Soc Clin Oncol Educ Book; 2013; ():374-80. PubMed ID: 23714551
[TBL] [Abstract][Full Text] [Related]
47. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
48. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy.
Adams HJA; Nievelstein RAJ; Kwee TC
Ann Hematol; 2016 Jan; 95(1):1-9. PubMed ID: 26482577
[TBL] [Abstract][Full Text] [Related]
49. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
Hoppe BS; Flampouri S; Zaiden R; Slayton W; Sandler E; Ozdemir S; Dang NH; Lynch JW; Li Z; Morris CG; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1053-1059. PubMed ID: 24928256
[TBL] [Abstract][Full Text] [Related]
50. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
51. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
Kamran SC; Jacene HA; Chen YH; Mauch PM; Ng AK
Leuk Lymphoma; 2018 Jun; 59(6):1384-1390. PubMed ID: 28937297
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
53. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
Specht L; Yahalom J; Illidge T; Berthelsen AK; Constine LS; Eich HT; Girinsky T; Hoppe RT; Mauch P; Mikhaeel NG; Ng A;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):854-62. PubMed ID: 23790512
[TBL] [Abstract][Full Text] [Related]
54. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
[TBL] [Abstract][Full Text] [Related]
55. Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.
Iberri DJ; Hoppe RT; Advani RH
Curr Treat Options Oncol; 2015 Sep; 16(9):45. PubMed ID: 26187795
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
57. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy.
Lavely WC; Delbeke D; Greer JP; Morgan DS; Byrne DW; Price RR; Hallahan DE
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):307-15. PubMed ID: 12957239
[TBL] [Abstract][Full Text] [Related]
58. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
59. Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy.
Uematsu M; Tarbell NJ; Silver B; Coleman CN; Rosenthal DS; Shulman LN; Canellos G; Weinstein H; Mauch P
Cancer; 1993 Jul; 72(1):207-12. PubMed ID: 7685241
[TBL] [Abstract][Full Text] [Related]
60. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Pediatr Hematol Oncol; 2015; 32(8):515-24. PubMed ID: 26561044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
